ArticleCancer cell international2024

Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways.

Hadeel Kheraldine et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.